Standard BioTools/$LAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Standard BioTools
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Ticker
$LAB
Sector
Primary listing
Employees
387
Headquarters
Website
LAB Metrics
BasicAdvanced
$350M
-
-$0.20
1.37
-
Price and volume
Market cap
$350M
Beta
1.37
52-week high
$1.72
52-week low
$0.90
Average daily volume
2.3M
Financial strength
Current ratio
4.194
Quick ratio
1.856
Long term debt to equity
5.972
Total debt to equity
7.266
Interest coverage (TTM)
-3,588.65%
Profitability
EBITDA (TTM)
-82.328
Gross margin (TTM)
49.86%
Net profit margin (TTM)
-87.77%
Operating margin (TTM)
-109.34%
Effective tax rate (TTM)
39.17%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-9.88%
Return on equity (TTM)
-13.13%
Valuation
Price to revenue (TTM)
4.013
Price to book
0.81
Price to tangible book (TTM)
0.81
Price to free cash flow (TTM)
-4.143
Free cash flow yield (TTM)
-24.14%
Free cash flow per share (TTM)
-0.217
Growth
Revenue change (TTM)
-6.24%
Earnings per share change (TTM)
-62.51%
3-year revenue growth (CAGR)
-4.49%
10-year revenue growth (CAGR)
-2.92%
3-year earnings per share growth (CAGR)
-56.76%
10-year earnings per share growth (CAGR)
-20.13%
What the Analysts think about LAB
Analyst ratings (Buy, Hold, Sell) for Standard BioTools stock.
LAB Financial Performance
Revenues and expenses
LAB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Standard BioTools stock?
Standard BioTools (LAB) has a market cap of $350M as of March 29, 2026.
What is the P/E ratio for Standard BioTools stock?
The price to earnings (P/E) ratio for Standard BioTools (LAB) stock is 0 as of March 29, 2026.
Does Standard BioTools stock pay dividends?
No, Standard BioTools (LAB) stock does not pay dividends to its shareholders as of March 29, 2026.
When is the next Standard BioTools dividend payment date?
Standard BioTools (LAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Standard BioTools?
Standard BioTools (LAB) has a beta rating of 1.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.